Esperion Therapeutics (ESPR) Operating Income Growth (1y) (2013 - 2026)
Esperion Therapeutics (ESPR) Operating Income Growth (1y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.42 Bn | 87.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.86 Bn | 32.12 Bn | 1.97 Bn | 25.63% |
| 3 | Zoetis | 32.46 Bn | 30.52 Bn | 1.62 Bn | -1.30% |
| 4 | Takeda Pharmaceutical | 27.52 Bn | 23.46 Bn | 4.39 Bn | -319.32% |
| 5 | United Therapeutics | 23.15 Bn | 20.99 Bn | 648.10 Mn | -14.89% |
| 6 | RedHill Biopharma | 21.17 Bn | 21.17 Bn | - | - |
| 7 | Viatris | 20.32 Bn | 18.51 Bn | 1.16 Bn | 97.23% |
| 8 | Neurocrine Biosciences | 17.74 Bn | 16.42 Bn | 800.70 Mn | 719.49% |
| 9 | Elanco Animal Health | 12.63 Bn | 12.20 Bn | 785.00 Mn | 21.25% |
| 10 | Esperion Therapeutics | 799.30 Mn | 643.14 Mn | 45.53 Mn | 70.22% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 70.22% |
| Dec 31, 2025 | 2,028.35% |
| Sep 30, 2025 | 37.86% |
| Jun 30, 2025 | 175.11% |
| Mar 31, 2025 | -130.57% |
| Dec 31, 2024 | 89.57% |
| Sep 30, 2024 | 41.79% |
| Jun 30, 2024 | 106.96% |
| Mar 31, 2024 | 248.69% |
| Dec 31, 2023 | 0.34% |
| Sep 30, 2023 | 33.85% |
| Jun 30, 2023 | 29.25% |
| Mar 31, 2023 | -13.06% |
| Dec 31, 2022 | 23.58% |
| Sep 30, 2022 | 25.33% |
| Jun 30, 2022 | -60.99% |
| Mar 31, 2022 | 48.10% |
| Dec 31, 2021 | 41.79% |
| Sep 30, 2021 | 30.80% |
| Jun 30, 2021 | -125.19% |